{"rows":[{"id":301,"title":"Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat Stress","normalized_title":"contribution of the serotonin 5 ht2a receptor to the therapeutic effect of psilocin on social behavior deficits in mice repeatedly exposed to social defeat stress","authors":"Ibi Daisuke, Takaba Rika, Yoshida Keisuke, Kawase Ririna, Kitagawa Hiroko, Matsushita Momoko, Ito Kana, Uno Shoya, Nishimura Fumiya, Kitagaki Shinji, Hiramatsu Masayuki","abstract":"ABSTRACT Psychedelics such as psilocybin and lysergic acid diethylamide (LSD) exert hallucinogenic effects through stimulation of serotonin 5-HT2A receptors (5-HT2ARs) in the cerebral cortex. In recent years, numerous reports have demonstrated that psychedelics are effective in treating various psychiatric disorders such as major depressive disorder (MDD), treatment-resistant depression (TRD), and anxiety-related disorders. We have previously reported that administration of psilocin, the active metabolite of psilocybin, produces antidepressant-like effects in mice. Furthermore, we found that this effect is mediated by 5-HT2AR activation. Since depression and other psychiatric disorders often lead to impairments in social behavior (e.g., social avoidance), the present study examined the effects of psilocin on social avoidance behavior in mice subjected to chronic social defeat stress (CSDS), a widely used model that closely models human psychosocial stress. Mice exposed to CSDS exhibited social avoidance behavior, whereas psilocin administration before the onset of CSDS had little effect on this behavior. In contrast, psilocin administration after the completion of CSDS ameliorated social avoidance in CSDS-exposed mice. This effect was blocked by pretreatment with a 5-HT2AR antagonist, indicating that psilocin exerts its therapeutic effects through 5-HT2AR activation. Taken together, psilocin exerts therapeutic effects on social avoidance behavior after stress through activation of 5-HT2AR, but not preventive effects when administered before stress, suggesting that psilocin may promote stress resilience rather than resistance.","journal":"Neuropsychopharmacology Reports","publication_date":"2026-08-31","publication_year":2026,"doi":"10.1002/npr2.70152","pubmed_id":"42379141","source_url":"https://doi.org/10.1002/npr2.70152","keywords":"","substance_tags":"psilocybin,psilocin","source_name":"Crossref","date_added":"2026-07-01 06:48:03","last_checked":"2026-07-05 01:20:21","raw_json":"{\"doi\":\"10.1002/npr2.70152\",\"reference_dois\":[\"10.1016/j.cell.2020.03.020\",\"10.1001/jamapsychiatry.2020.3285\",\"10.1007/s00210‐023‐02778‐x\",\"10.3390/pharmaceutics17040411\",\"10.3389/fphar.2024.1391689\",\"10.1542/peds.2008‐1215\",\"10.1186/s12888‐023‐04681‐4\",\"10.1073/pnas.2312662120\",\"10.1016/j.bpsgos.2021.12.009\",\"10.1016/j.biopsych.2016.06.012\",\"10.1016/j.neuroscience.2021.01.029\",\"10.1016/j.neures.2022.12.015\",\"10.1038/nprot.2011.361\",\"10.1016/s0031‐9384(01)00490‐5\",\"10.1111/ejn.15812\",\"10.1016/j.neuropharm.2018.01.016\",\"10.1021/acschemneuro.9b00493\",\"10.1016/j.neuron.2007.01.008\",\"10.1016/j.bbi.2012.12.017\"],\"reference_count\":19,\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W7166665532\",\"openalex_url\":\"https://openalex.org/W7166665532\",\"openalex_relevance_score\":12,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\",\"title:psilocin\",\"abstract:psilocin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1970090557\",\"https://openalex.org/W1977593923\",\"https://openalex.org/W2009134620\",\"https://openalex.org/W2430804118\",\"https://openalex.org/W2783004241\",\"https://openalex.org/W3010499243\",\"https://openalex.org/W3015140823\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3127490177\",\"https://openalex.org/W4206083694\",\"https://openalex.org/W4293199581\",\"https://openalex.org/W4312054389\",\"https://openalex.org/W4389040484\",\"https://openalex.org/W4396224564\",\"https://openalex.org/W4408808337\"],\"authorships\":[{\"id\":\"https://openalex.org/A5139664214\",\"display_name\":\"Daisuke Ibi\",\"orcid\":null},{\"id\":\"https://openalex.org/A5076092672\",\"display_name\":\"Rika Takaba\",\"orcid\":null},{\"id\":\"https://openalex.org/A5079107661\",\"display_name\":\"Keisuke Yoshida\",\"orcid\":\"https://orcid.org/0000-0002-8384-9418\"},{\"id\":\"https://openalex.org/A5108412221\",\"display_name\":\"R. Kawase\",\"orcid\":null},{\"id\":\"https://openalex.org/A5048244424\",\"display_name\":\"Hiroko Kitagawa\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139661865\",\"display_name\":\"Momoko Matsushita\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139634014\",\"display_name\":\"Kana Ito\",\"orcid\":null},{\"id\":\"https://openalex.org/A5030080970\",\"display_name\":\"Shoya Uno\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139632842\",\"display_name\":\"Fumiya Nishimura\",\"orcid\":null},{\"id\":\"https://openalex.org/A5014830673\",\"display_name\":\"Shinji Kitagaki\",\"orcid\":\"https://orcid.org/0000-0001-7496-7773\"},{\"id\":\"https://openalex.org/A5139711108\",\"display_name\":\"Masayuki Hiramatsu\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210189692\",\"source_display_name\":\"Neuropsychopharmacology Reports\",\"landing_page_url\":\"https://doi.org/10.1002/npr2.70152\",\"is_oa\":true}}}","topic_tags":"Depression,Anxiety,Receptor Pharmacology,Resilience,Animal Study,Treatment-Resistant Depression","study_type":"Animal Study","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7166665532"},{"id":1922,"title":"Phase 1 trial suggests benefit of psilocybin in OCD treatment","normalized_title":"phase 1 trial suggests benefit of psilocybin in ocd treatment","authors":"","abstract":"A Phase 1 trial comprising 15 patients has found that repeated high-dose administration of psilocybin was more effective than low-dose psilocybin or placebo in reducing symptoms of obsessive-compulsive disorder (OCD). Psilocybin was generally well-tolerated, with no reports of serious adverse events.","journal":"The Brown University Psychopharmacology Update","publication_date":"2026-07-31","publication_year":2026,"doi":"10.1002/pu.31474","pubmed_id":null,"source_url":"https://doi.org/10.1002/pu.31474","keywords":"","substance_tags":"psilocybin","source_name":"Crossref","date_added":"2026-07-01 06:49:23","last_checked":"2026-07-05 01:20:21","raw_json":"{\"doi\":\"10.1002/pu.31474\",\"reference_dois\":[],\"reference_count\":0,\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W7166436628\",\"openalex_url\":\"https://openalex.org/W7166436628\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[],\"primary_location\":{\"source_id\":\"https://openalex.org/S1022177896\",\"source_display_name\":\"The Brown University Psychopharmacology Update\",\"landing_page_url\":\"https://doi.org/10.1002/pu.31474\",\"is_oa\":false}}}","topic_tags":"OCD,Clinical Trial,Adverse Events","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7166436628"},{"id":5672,"title":"Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development","normalized_title":"naturally derived psilocybin for therapeutic use a six criterion framework for evidence safety and benefit risk considerations in policy and clinical development","authors":"Enriquez-Geppert Stefanie, Bevers Lisa, Rosander Arvid, Fodran Peter, Polito Vince","abstract":"Naturally derived psilocybin is widely used, yet its therapeutic potential, pharmacological distinctiveness and regulatory feasibility remain understudied. This review evaluates the potential of naturally derived psilocybin using a six-criterion framework to evaluate: (1) therapeutic benefit, (2) safety and tolerability, (3) pharmacological uniqueness vs. synthetic psilocybin, (4) identity and composition control, (5) dose precision and stability, and (6) ecological sustainability. This paper answers three key questions about naturally derived psilocybin: Does it show therapeutic potential? Does it differ from synthetic psilocybin? Can it meet medicinal standards? Findings suggest perceived therapeutic benefits from naturally derived psilocybin across mental health domains, though evidence of causal efficacy is mixed. Safety profiles are favorable but context-dependent, with risks in vulnerable populations. Some preliminary preclinical evidence indicates possible entourage effects, but human validation is lacking. Dose precision varies, with purified psilocybin being most reliable, followed by standardized extracts, alcoholic, aqueous, and whole biomass preparations. Scalable cultivation is feasible but faces sustainability challenges. Key gaps include a lack of controlled trials, longitudinal safety evaluations, and standardization. We provide a phased research roadmap, which proposes short-term studies to establish safety, mid-term mechanistic and standardization efforts, and long-term integration into therapeutic, cultural, and ecological systems. This review highlights the promise of naturally derived psilocybin but underscores the need for rigorous evidence to support regulatory acceptance and clinical use.","journal":"Biomolecules","publication_date":"2026-07-02","publication_year":2026,"doi":"10.3390/biom16070983","pubmed_id":null,"source_url":"https://doi.org/10.3390/biom16070983","keywords":"","substance_tags":"psilocybin","source_name":"Crossref","date_added":"2026-07-05 01:20:15","last_checked":"2026-07-05 01:20:21","raw_json":"{\"doi\":\"10.3390/biom16070983\",\"reference_dois\":[\"10.1016/j.psychres.2023.115531\",\"10.1016/j.neubiorev.2025.106163\",\"10.1016/bs.irn.2025.03.001\",\"10.1016/j.ajp.2024.104242\",\"10.1057/s41292-025-00369-y\",\"10.1556/2054.2025.00432\",\"10.1556/2054.2023.00297\",\"10.3389/fpsyt.2024.1169686\",\"10.1615/intjmedmushr.v10.i3.20\",\"10.1016/j.funbio.2022.01.003\",\"10.1038/s41429-020-0311-8\",\"10.4103/indianjpsychiatry.indianjpsychiatry_707_23\",\"10.1007/978-981-97-1203-8\",\"10.3389/fpsyg.2021.747999\",\"10.1038/npp.2017.84\",\"10.1016/b0-08-043076-7/00180-7\",\"10.2307/3090197\",\"10.1038/s41467-022-32310-3\",\"10.7326/0003-4819-144-5-200603070-00013\",\"10.1016/j.jep.2017.08.015\",\"10.1556/2054.2020.00159\",\"10.1016/j.drugpo.2024.104507\",\"10.3389/fpsyt.2023.1199642\",\"10.1186/s12955-020-01423-y\",\"10.1371/journal.pone.0321648\",\"10.1556/2054.2025.00375\",\"10.1089/psymed.2023.0074\",\"10.1177/0269881115598338\",\"10.1016/j.jpsychores.2018.04.004\",\"10.3389/fpsyt.2023.1169692\",\"10.1177/0269881114565653\",\"10.1177/0269881117735685\",\"10.1177/0269881114568039\",\"10.1371/journal.pone.0063972\",\"10.3389/fpsyt.2021.780696\",\"10.1177/20494637251319497\",\"10.1177/02698811231158245\",\"10.1177/02698811221131997\",\"10.1016/j.jad.2024.10.058\",\"10.3389/fphar.2018.00897\",\"10.3389/fphar.2021.623985\",\"10.1556/2054.2021.00162\",\"10.1016/j.neubiorev.2022.104706\",\"10.1177/0269881120953994\",\"10.1038/s41598-021-01811-4\",\"10.1038/s41598-022-14512-3\",\"10.3389/fpsyt.2019.00672\",\"10.1007/s00213-020-05477-0\",\"10.1192/j.eurpsy.2024.8\",\"10.1001/jamapsychiatry.2025.0044\",\"10.56522/bmchap.0130010280003\",\"10.1111/anoc.12168\",\"10.1186/s13002-025-00779-z\",\"10.1080/00275514.2024.2363137\",\"10.1111/anoc.12163\",\"10.1556/2054.2025.00436\",\"10.1080/02791072.2023.2246459\",\"10.1177/0269881119857204\",\"10.1007/s00213-018-5049-7\",\"10.1080/02791072.2019.1580804\",\"10.7554/elife.62878\",\"10.1038/s41398-022-02039-0\",\"10.1177/02698811211050556\",\"10.1016/j.neuropharm.2025.110722\",\"10.1016/j.neuropharm.2025.110732\",\"10.1098/rstb.2023.0095\",\"10.1016/j.neuropharm.2018.05.012\",\"10.1016/j.euroneuro.2013.12.006\",\"10.1093/qjmed/hcu145\",\"10.1177/0269881108093587\",\"10.1016/j.ijchp.2022.100349\",\"10.1016/j.tips.2023.12.007\",\"10.1177/02698811221084063\",\"10.1371/journal.pone.0229067\",\"10.1038/s41598-023-40856-5\",\"10.1002/hup.2234\",\"10.1177/02698811231211219\",\"10.1177/02698811231179910\",\"10.1007/s00213-024-06585-x\",\"10.1080/02791072.2024.2368617\",\"10.1016/j.toxicon.2025.108450\",\"10.1021/acscentsci.5c01146\",\"10.3897/imafungus.16.148070\",\"10.1080/02791072.2024.2401982\",\"10.9758/cpn.24.1180\",\"10.1186/s12888-024-06303-z\",\"10.1016/j.ajoc.2025.102359\",\"10.3390/ijms23126713\",\"10.1001/jamanetworkopen.2024.5960\",\"10.1016/j.nsa.2024.104060\",\"10.1038/s41386-022-01297-2\",\"10.1038/s41386-019-0324-9\",\"10.1002/anie.201705489\",\"10.1002/cbic.202200183\",\"10.1016/j.euroneuro.2016.05.001\",\"10.1038/s41386-022-01389-z\",\"10.3389/fncel.2016.00272\",\"10.1016/j.tips.2025.08.012\",\"10.1007/s43440-024-00660-y\",\"10.1523/jneurosci.1384-23.2023\",\"10.1038/s41380-025-03257-w\",\"10.1038/s41467-023-44016-1\",\"10.1038/s41380-025-03100-2\",\"10.1126/science.abl8615\",\"10.1073/pnas.2416106122\",\"10.1126/science.adf0435\",\"10.1038/s41586-024-07624-5\",\"10.1016/j.nlm.2013.04.015\",\"10.1016/j.neuron.2012.08.036\",\"10.1016/j.tibs.2024.02.001\",\"10.1038/s41593-023-01316-5\",\"10.1016/j.neuron.2025.06.012\",\"10.1038/s41583-019-0212-7\",\"10.1016/j.mehy.2019.109406\",\"10.1038/s41514-025-00244-x\",\"10.1016/s0014-2999(98)00392-6\",\"10.3389/fpls.2018.01969\",\"10.1002/chem.201904363\",\"10.1038/s41598-026-39483-7\",\"10.3390/toxins7041018\",\"10.1038/s41380-024-02477-w\",\"10.1021/acs.jnatprod.9b01061\",\"10.1111/bph.16466\",\"10.1271/bbb.90095\",\"10.1192/j.eurpsy.2022.2297\",\"10.1080/02791072.2024.2446445\",\"10.1615/intjmedmushr.v7.i12.280\",\"10.3390/ph18070989\",\"10.3390/ph18030380\",\"10.1002/jps.2600571006\",\"10.3390/jof8060598\",\"10.1055/s-2007-969526\",\"10.1520/jfs2004276\",\"10.1021/np50015a023\",\"10.1016/0378-8741(82)90013-7\",\"10.1002/jps.2600541104\",\"10.1002/jps.2600560132\",\"10.1002/jps.2600571007\",\"10.1016/s0015-3796(89)80023-x\",\"10.1002/cbic.202200249\",\"10.1016/j.jep.2023.117415\",\"10.1016/s0021-9673(01)99190-3\",\"10.1016/s0021-9673(01)81831-8\",\"10.1002/jobm.3620290608\",\"10.1016/s0379-0738(00)00211-5\",\"10.1021/acsomega.5c02751\",\"10.1016/j.talanta.2004.11.031\",\"10.1016/j.scijus.2018.08.005\",\"10.1016/j.aca.2023.342161\",\"10.1615/intjmedmushrooms.2024056373\",\"10.1016/j.forsciint.2003.08.009\",\"10.1520/jfs14725j\",\"10.1080/00032717908067906\",\"10.1016/0021-9673(92)80287-5\",\"10.1093/jat/22.1.45\",\"10.1515/znc-1988-7-806\",\"10.1016/s0021-9673(00)85700-3\",\"10.1016/s0021-9673(01)96375-7\",\"10.1016/s0015-3796(86)80079-8\",\"10.1016/s0007-1536(69)80066-5\",\"10.1016/s0378-4347(97)00127-8\",\"10.1016/j.talanta.2004.11.038\",\"10.1016/s1355-0306(06)71579-9\",\"10.1071/ch9700853\",\"10.1016/s0379-0738(98)00168-6\",\"10.1556/2054.2023.00332\",\"10.1124/jpet.122.001454\",\"10.1002/dta.2950\",\"10.1093/jaoacint/qsaf072\",\"10.1002/anie.201910175\",\"10.1016/j.biortech.2021.126157\",\"10.1007/s00253-018-9226-8\",\"10.3389/fsufs.2022.1026508\",\"10.1016/j.cub.2023.10.059\",\"10.3389/fmicb.2024.1337398\",\"10.1007/978-981-19-5041-4\",\"10.3390/f14020382\"],\"reference_count\":213,\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W7167239267\",\"openalex_url\":\"https://openalex.org/W7167239267\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W113471454\",\"https://openalex.org/W294456830\",\"https://openalex.org/W1903260451\",\"https://openalex.org/W1948675593\",\"https://openalex.org/W1970807094\",\"https://openalex.org/W1977511640\",\"https://openalex.org/W1981430494\",\"https://openalex.org/W1983348446\",\"https://openalex.org/W1984431812\",\"https://openalex.org/W1984696579\",\"https://openalex.org/W1997161439\",\"https://openalex.org/W2002070445\",\"https://openalex.org/W2002488633\",\"https://openalex.org/W2009390034\",\"https://openalex.org/W2010212334\",\"https://openalex.org/W2012142575\",\"https://openalex.org/W2014761647\",\"https://openalex.org/W2027191929\",\"https://openalex.org/W2027679864\",\"https://openalex.org/W2031832463\",\"https://openalex.org/W2035946761\",\"https://openalex.org/W2045514302\",\"https://openalex.org/W2050577168\",\"https://openalex.org/W2057353445\",\"https://openalex.org/W2067240620\",\"https://openalex.org/W2067405887\",\"https://openalex.org/W2074146187\",\"https://openalex.org/W2080507858\",\"https://openalex.org/W2081244857\",\"https://openalex.org/W2092517056\",\"https://openalex.org/W2093746690\",\"https://openalex.org/W2094530511\",\"https://openalex.org/W2097999899\",\"https://openalex.org/W2108432873\",\"https://openalex.org/W2111452082\",\"https://openalex.org/W2113099805\",\"https://openalex.org/W2126698385\",\"https://openalex.org/W2130119797\",\"https://openalex.org/W2135562277\",\"https://openalex.org/W2143976354\",\"https://openalex.org/W2164453648\",\"https://openalex.org/W2164981793\",\"https://openalex.org/W2165984877\",\"https://openalex.org/W2166997091\",\"https://openalex.org/W2332145281\",\"https://openalex.org/W2333398807\",\"https://openalex.org/W2398898762\",\"https://openalex.org/W2409505272\",\"https://openalex.org/W2549512121\",\"https://openalex.org/W2610144880\",\"https://openalex.org/W2741562499\",\"https://openalex.org/W2745417039\",\"https://openalex.org/W2766270028\",\"https://openalex.org/W2797787314\",\"https://openalex.org/W2806419184\",\"https://openalex.org/W2883434454\",\"https://openalex.org/W2888502690\",\"https://openalex.org/W2894846833\",\"https://openalex.org/W2907562503\",\"https://openalex.org/W2914255920\",\"https://openalex.org/W2917218353\",\"https://openalex.org/W2951080359\",\"https://openalex.org/W2958413903\",\"https://openalex.org/W2969627127\",\"https://openalex.org/W2971683016\",\"https://openalex.org/W2975681496\",\"https://openalex.org/W2983552824\",\"https://openalex.org/W2988070888\",\"https://openalex.org/W3004910645\",\"https://openalex.org/W3007379062\",\"https://openalex.org/W3008629222\",\"https://openalex.org/W3025824861\",\"https://openalex.org/W3036680904\",\"https://openalex.org/W3092151265\",\"https://openalex.org/W3094690508\",\"https://openalex.org/W3126260393\",\"https://openalex.org/W3134377893\",\"https://openalex.org/W3152417644\",\"https://openalex.org/W3156510154\",\"https://openalex.org/W3207288198\",\"https://openalex.org/W3211089224\",\"https://openalex.org/W3211842562\",\"https://openalex.org/W4200583144\",\"https://openalex.org/W4210474529\",\"https://openalex.org/W4211114943\",\"https://openalex.org/W4214649547\",\"https://openalex.org/W4221018864\",\"https://openalex.org/W4225114051\",\"https://openalex.org/W4226060882\",\"https://openalex.org/W4280616839\",\"https://openalex.org/W4281253144\",\"https://openalex.org/W4281661929\",\"https://openalex.org/W4283011889\",\"https://openalex.org/W4283719838\",\"https://openalex.org/W4289518537\",\"https://openalex.org/W4290756542\",\"https://openalex.org/W4291383525\",\"https://openalex.org/W4293802544\",\"https://openalex.org/W4294203445\",\"https://openalex.org/W4296373810\",\"https://openalex.org/W4304004488\",\"https://openalex.org/W4311448180\",\"https://openalex.org/W4311477082\",\"https://openalex.org/W4313343874\",\"https://openalex.org/W4317600184\",\"https://openalex.org/W4320729123\",\"https://openalex.org/W4321033185\",\"https://openalex.org/W4323294129\",\"https://openalex.org/W4379469019\",\"https://openalex.org/W4379967727\",\"https://openalex.org/W4382931678\",\"https://openalex.org/W4385969211\",\"https://openalex.org/W4386069067\",\"https://openalex.org/W4386165916\",\"https://openalex.org/W4386861633\",\"https://openalex.org/W4387521434\",\"https://openalex.org/W4388486766\",\"https://openalex.org/W4388714298\",\"https://openalex.org/W4388827052\",\"https://openalex.org/W4389306740\",\"https://openalex.org/W4389793820\",\"https://openalex.org/W4389912710\",\"https://openalex.org/W4390732376\",\"https://openalex.org/W4391177392\",\"https://openalex.org/W4391784419\",\"https://openalex.org/W4391817579\",\"https://openalex.org/W4391924240\",\"https://openalex.org/W4391970820\",\"https://openalex.org/W4392350911\",\"https://openalex.org/W4392888270\",\"https://openalex.org/W4393954510\",\"https://openalex.org/W4393993168\",\"https://openalex.org/W4394693583\",\"https://openalex.org/W4396518351\",\"https://openalex.org/W4398182074\",\"https://openalex.org/W4399276098\",\"https://openalex.org/W4399897612\",\"https://openalex.org/W4399977372\",\"https://openalex.org/W4400043767\",\"https://openalex.org/W4400240547\",\"https://openalex.org/W4400729513\",\"https://openalex.org/W4401981685\",\"https://openalex.org/W4402516078\",\"https://openalex.org/W4402564741\",\"https://openalex.org/W4402678596\",\"https://openalex.org/W4403450928\",\"https://openalex.org/W4403615858\",\"https://openalex.org/W4403628871\",\"https://openalex.org/W4405735206\",\"https://openalex.org/W4407157019\",\"https://openalex.org/W4407380636\",\"https://openalex.org/W4408041085\",\"https://openalex.org/W4408226956\",\"https://openalex.org/W4408591537\",\"https://openalex.org/W4409415903\",\"https://openalex.org/W4409449345\",\"https://openalex.org/W4409676357\",\"https://openalex.org/W4410005099\",\"https://openalex.org/W4410030136\",\"https://openalex.org/W4410444635\",\"https://openalex.org/W4410645269\",\"https://openalex.org/W4410946123\",\"https://openalex.org/W4411116696\",\"https://openalex.org/W4411961287\",\"https://openalex.org/W4411981579\",\"https://openalex.org/W4412073006\",\"https://openalex.org/W4412102657\",\"https://openalex.org/W4412138274\",\"https://openalex.org/W4412520959\",\"https://openalex.org/W4413116294\",\"https://openalex.org/W4413975935\",\"https://openalex.org/W4414031406\",\"https://openalex.org/W4414171615\",\"https://openalex.org/W4414267802\",\"https://openalex.org/W4415356003\",\"https://openalex.org/W4415775160\",\"https://openalex.org/W7128912015\"],\"authorships\":[{\"id\":\"https://openalex.org/A5079573410\",\"display_name\":\"Stefanie Enriquez-Geppert\",\"orcid\":\"https://orcid.org/0000-0001-7305-0111\"},{\"id\":\"https://openalex.org/A5139990795\",\"display_name\":\"Lisa Bevers\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139974022\",\"display_name\":\"Arvid Rosander\",\"orcid\":null},{\"id\":\"https://openalex.org/A5079289829\",\"display_name\":\"Peter Fodran\",\"orcid\":\"https://orcid.org/0000-0003-0348-8331\"},{\"id\":\"https://openalex.org/A5045686739\",\"display_name\":\"Vince Polito\",\"orcid\":\"https://orcid.org/0000-0003-3242-9074\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210236520\",\"source_display_name\":\"Biomolecules\",\"landing_page_url\":\"https://doi.org/10.3390/biom16070983\",\"is_oa\":true}}}","topic_tags":"Review Article,Animal Study,Safety","study_type":"Review Article","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7167239267"},{"id":3978,"title":"Trajectories of psychedelic-assisted change: An observational study of a psilocybin retreat program followed by psychotherapeutic interventions","normalized_title":"trajectories of psychedelic assisted change an observational study of a psilocybin retreat program followed by psychotherapeutic interventions","authors":"Whitfield Henry J., Schepers Jan, Mason Natasha L., Luca Maria, Kuypers Kim P. C.","abstract":"Abstract Despite growing interest in psychedelic-assisted psychotherapy, research investigating the psychotherapeutic components is lacking. This leaves unanswered questions regarding the psychotherapy's necessity and form. This observational study addresses this gap by measuring the outcomes of a psilocybin truffle retreat, followed by the outcomes of two psychotherapy interventions that targeted psychological content from the retreat ( n = 50). Participants attended an Acceptance and Commitment Therapy (ACT)-informed psilocybin retreat program followed by psychotherapy. Mid-data collection the psychotherapy intervention was revised: ACT-SPT ( n = 23; self-perspective taking and cognitive defusion) was altered to ACT-PMNR ( n = 27; Psychedelic Memory Network Reexperiencing). Both approaches aimed to support long-term psychological change. Participants completed measures of Depression, Anxiety, Stress (DASS-21), Valued Living (VLQ), and measures of Psychological Flexibility, Mindfulness, Cognitive Fusion, Well-being and Life Functioning at four time points: baseline, post-psilocybin, post-psychotherapy and follow-up. For the combined effect of retreat and subsequent interventions, a Linear Mixed Model (LMM) analysis found significant changes in all measures. Comparing psychotherapy trajectories, there was a significant Time × Intervention interaction for DASS-21 (Anxiety), CORE-5 (Well-being, Life Functioning). During the post-psilocybin period, ACT-SPT trajectories drifted towards baseline levels, whilst ACT-PMNR continued to improve. Long-term LMM follow-up of ACT-PMNR trajectories showed significant change across all measures. Penalized spline growth curves showed that post-therapy change exceeded baseline-to-post-retreat change. At follow-up these trajectories often sustained or further improved. Conclusions Targeted post-psilocybin interventions may further build on the initial psilocybin retreat result. These interventions may drive measurable changes in the specific domains they engage. Randomized studies are warranted to confirm these findings.","journal":"Journal of Psychedelic Studies","publication_date":"2026-07-02","publication_year":2026,"doi":"10.1556/2054.2026.00530","pubmed_id":null,"source_url":"https://doi.org/10.1556/2054.2026.00530","keywords":"","substance_tags":"psilocybin","source_name":"Crossref","date_added":"2026-07-04 01:20:27","last_checked":"2026-07-05 01:20:21","raw_json":"{\"doi\":\"10.1556/2054.2026.00530\",\"reference_dois\":[\"10.1007/s00213-024-06620-x\",\"10.1007/bf00401404\",\"10.1177/1073191105283504\",\"10.1177/1073191107313003\",\"10.1002/9780470687994.ch8\",\"10.1038/s41598-020-59282-y\",\"10.1001/jamapsychiatry.2022.2096\",\"10.1016/j.beth.2011.03.007\",\"10.1093/oxfordhb/9780190088224.013.29\",\"10.1007/s00213-017-4771-x\",\"10.1177/0269881118754710\",\"10.1097/psy.0000000000000233\",\"10.1348/014466503321903544\",\"10.1016/j.jpsychires.2021.08.017\",\"10.3389/fpsyg.2018.01028\",\"10.1371/journal.pone.0246434\",\"10.1192/bjp.180.1.51\",\"10.3758/bf03193146\",\"10.1016/j.jcbs.2016.05.003\",\"10.1080/09540261.2018.1486289\",\"10.1300/j146v12n01_08\",\"10.1016/j.beth.2013.08.001\",\"10.1177/0269881116675513\",\"10.1016/s2215-0366(23)00363-2\",\"10.1037/pas0000263\",\"10.3389/fpsyt.2022.946615\",\"10.1007/bf03395492\",\"10.1016/s0006-3223(01)01157-x\",\"10.1016/j.psyneuen.2008.03.008\",\"10.1192/bjp.bp.112.125286\",\"10.1038/s41598-020-61169-x\",\"10.1177/0269881114548296\",\"10.1080/03004279.2023.2257216\",\"10.1002/cpp.479\",\"10.1016/0005-7967(94)00075-u\",\"10.1080/02791072.2020.1769878\",\"10.1037/a0026070\",\"10.3389/fphar.2018.00256\",\"10.3389/fpsyt.2022.1025726\",\"10.1016/j.brat.2003.10.008\",\"10.1111/acps.13778\",\"10.2147/ndt.s432537\",\"10.1111/psyp.14756\",\"10.1038/s41586-023-06204-3\",\"10.1177/0269881118780612\",\"10.1016/j.cell.2020.03.020\",\"10.1080/00207594.2012.755535\",\"10.1001/jamanetworkopen.2022.49422\",\"10.1176/appi.ajp.2018.18070834\",\"10.1176/appi.ajp.20220216\",\"10.1001/jamanetworkopen.2023.12434\",\"10.1177/0022167816670996\",\"10.1177/0269881116675512\",\"10.1176/appi.psychotherapy.2002.56.1.59\",\"10.1177/20503245241235100\",\"10.1016/j.jcbs.2024.100854\",\"10.1016/j.jcbs.2014.06.001\",\"10.1037/met0000193\",\"10.1177/0022167817715966\",\"10.1002/da.23065\",\"10.1038/s41598-023-36184-3\",\"10.3389/fpsyt.2021.727572\",\"10.1007/bf03395706\",\"10.1016/j.beth.2014.07.002\"],\"reference_count\":140,\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W7167262029\",\"openalex_url\":\"https://openalex.org/W7167262029\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W848231126\",\"https://openalex.org/W1499135245\",\"https://openalex.org/W1723026158\",\"https://openalex.org/W1749626057\",\"https://openalex.org/W1818523973\",\"https://openalex.org/W1966524739\",\"https://openalex.org/W1990781714\",\"https://openalex.org/W2004719903\",\"https://openalex.org/W2007316404\",\"https://openalex.org/W2009710620\",\"https://openalex.org/W2011362078\",\"https://openalex.org/W2034824117\",\"https://openalex.org/W2038015193\",\"https://openalex.org/W2062682953\",\"https://openalex.org/W2062989629\",\"https://openalex.org/W2064471675\",\"https://openalex.org/W2076298754\",\"https://openalex.org/W2087484885\",\"https://openalex.org/W2114350740\",\"https://openalex.org/W2122459973\",\"https://openalex.org/W2137111843\",\"https://openalex.org/W2141674457\",\"https://openalex.org/W2148011665\",\"https://openalex.org/W2165847290\",\"https://openalex.org/W2255259502\",\"https://openalex.org/W2263745924\",\"https://openalex.org/W2395013989\",\"https://openalex.org/W2525190545\",\"https://openalex.org/W2558412547\",\"https://openalex.org/W2559739670\",\"https://openalex.org/W2626493232\",\"https://openalex.org/W2767530231\",\"https://openalex.org/W2788854095\",\"https://openalex.org/W2796179442\",\"https://openalex.org/W2807347332\",\"https://openalex.org/W2809850625\",\"https://openalex.org/W2886736785\",\"https://openalex.org/W2900604419\",\"https://openalex.org/W2935676591\",\"https://openalex.org/W3005441929\",\"https://openalex.org/W3009608926\",\"https://openalex.org/W3015140823\",\"https://openalex.org/W3035643259\",\"https://openalex.org/W3038388367\",\"https://openalex.org/W3128065860\",\"https://openalex.org/W3196180891\",\"https://openalex.org/W4200524305\",\"https://openalex.org/W4213367182\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4296710292\",\"https://openalex.org/W4304842777\",\"https://openalex.org/W4311508922\",\"https://openalex.org/W4313544481\",\"https://openalex.org/W4375954983\",\"https://openalex.org/W4380089845\",\"https://openalex.org/W4380684709\",\"https://openalex.org/W4386603958\",\"https://openalex.org/W4389606379\",\"https://openalex.org/W4391053730\",\"https://openalex.org/W4392249465\",\"https://openalex.org/W4398774731\",\"https://openalex.org/W4404565171\",\"https://openalex.org/W4405021720\",\"https://openalex.org/W4406768953\"],\"authorships\":[{\"id\":\"https://openalex.org/A5109831612\",\"display_name\":\"Henry J. Whitfield\",\"orcid\":null},{\"id\":\"https://openalex.org/A5016439728\",\"display_name\":\"Jan Schepers\",\"orcid\":\"https://orcid.org/0000-0002-6511-7651\"},{\"id\":\"https://openalex.org/A5139963227\",\"display_name\":\"Natasha L. Mason\",\"orcid\":null},{\"id\":\"https://openalex.org/A5017592857\",\"display_name\":\"Maria Luca\",\"orcid\":\"https://orcid.org/0000-0003-0416-4718\"},{\"id\":\"https://openalex.org/A5024651565\",\"display_name\":\"Kim P. C. Kuypers\",\"orcid\":\"https://orcid.org/0000-0001-7634-3809\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S4210226251\",\"source_display_name\":\"Journal of Psychedelic Studies\",\"landing_page_url\":\"https://doi.org/10.1556/2054.2026.00530\",\"is_oa\":true}}}","topic_tags":"Depression,Anxiety,Wellbeing,Psychological Flexibility,Observational Study,Drug Interactions","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7167262029"},{"id":3983,"title":"Surprising Variability in Tryptamine Profiles of Psilocybe cubensis Fruiting Bodies: Inter- and Intra-Strain Differences Across 14 Strains Cultivated Under Controlled Conditions","normalized_title":"surprising variability in tryptamine profiles of psilocybe cubensis fruiting bodies inter and intra strain differences across 14 strains cultivated under controlled conditions","authors":"Amiel Sharchaton, Shilat Parsha, Sara P. Azerrad, Yaron Dekel, Nisreen Rabah, Tomáš Páleníček, Eyal Kurzbaum","abstract":"Psilocybin-producing mushrooms exhibit considerable biochemical diversity, yet the extent of variability among strains within a single species under standardized conditions remains insufficiently characterized. In this study, we quantified psilocybin, psilocin, baeocystin, norbaeocystin, aeruginascin, and norpsilocin in the fruiting bodies of 14 distinct strains of Psilocybe cubensis. The mushroom strains were cultivated, dried, extracted, and analyzed under uniform laboratory conditions. Despite strict methodological standardization, total tryptamine concentrations varied by more than 7.8-fold among strains (from 2.62 to 20.65 mg/g), with psilocybin consistently emerging as the dominant compound. Analysis of individual fruiting bodies within the selected strains revealed substantial intra-strain variability, with coefficients of variation for psilocybin ranging from 12.81% to 23.39% between individual fruiting bodies. These findings demonstrate that both inter- and intra-strain biochemical heterogeneity persist even under controlled conditions, underscoring the challenges of standardizing whole mushroom preparations for research or therapeutic use. Our results highlight the importance of strain selection, rigorous chemical profiling, and dosing precision in future pharmacological and clinical applications of P. cubensis.","journal":"Journal of Fungi","publication_date":"2026-07-01","publication_year":2026,"doi":"10.3390/jof12070486","pubmed_id":null,"source_url":"https://doi.org/10.3390/jof12070486","keywords":"Tryptamine, Psilocybin, Biology, Mushroom, Strain (injury), Botany, Agaricales, Edible mushroom, Phenotype, Ecology, Psychedelics and Drug Studies, Chemical synthesis and alkaloids, Silymarin and Mushroom Poisoning","substance_tags":"psilocybin,psilocin","source_name":"OpenAlex","date_added":"2026-07-04 01:20:30","last_checked":"2026-07-05 01:20:21","raw_json":"{\"openalex_id\":\"https://openalex.org/W7167101970\",\"openalex_url\":\"https://openalex.org/W7167101970\",\"openalex_relevance_score\":10,\"openalex_relevance_reasons\":[\"abstract:psilocybin\",\"metadata:psilocybin\",\"abstract:psilocin\",\"contextual-mushroom-match\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2398867243\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W3094690508\",\"https://openalex.org/W3201625402\",\"https://openalex.org/W4211114943\",\"https://openalex.org/W4212903385\",\"https://openalex.org/W4256228556\",\"https://openalex.org/W4281661929\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4309210963\",\"https://openalex.org/W4310466310\",\"https://openalex.org/W4311043198\",\"https://openalex.org/W4386305655\",\"https://openalex.org/W4386314831\",\"https://openalex.org/W4388714298\",\"https://openalex.org/W4389150740\",\"https://openalex.org/W4389912710\",\"https://openalex.org/W4391970820\",\"https://openalex.org/W4403328142\",\"https://openalex.org/W4404004370\",\"https://openalex.org/W4406904437\",\"https://openalex.org/W4408226956\",\"https://openalex.org/W4409693197\",\"https://openalex.org/W4411981579\"],\"authorships\":[{\"id\":\"https://openalex.org/A5133076583\",\"display_name\":\"Amiel Sharchaton\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139316543\",\"display_name\":\"Shilat Parsha\",\"orcid\":null},{\"id\":\"https://openalex.org/A5060251977\",\"display_name\":\"Sara P. Azerrad\",\"orcid\":\"https://orcid.org/0000-0002-4634-7216\"},{\"id\":\"https://openalex.org/A5036271700\",\"display_name\":\"Yaron Dekel\",\"orcid\":\"https://orcid.org/0000-0003-1853-9920\"},{\"id\":\"https://openalex.org/A5139925103\",\"display_name\":\"Nisreen Rabah\",\"orcid\":null},{\"id\":\"https://openalex.org/A5056888000\",\"display_name\":\"Tomáš Páleníček\",\"orcid\":\"https://orcid.org/0000-0002-3109-9539\"},{\"id\":\"https://openalex.org/A5009213075\",\"display_name\":\"Eyal Kurzbaum\",\"orcid\":\"https://orcid.org/0000-0002-8258-9407\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S2737643958\",\"source_display_name\":\"Journal of Fungi\",\"landing_page_url\":\"https://doi.org/10.3390/jof12070486\",\"is_oa\":true}}","topic_tags":"General","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7167101970"},{"id":3976,"title":"Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions.","normalized_title":"psilocybin as a transdiagnostic treatment for eating disorders and comorbid psychopathology implications for clinical nosology and research directions","authors":"Koning E, Richard J, Keshen A.","abstract":"ObjectiveEating disorders (EDs) are characterized by high rates of psychiatric comorbidity and suboptimal treatment outcomes. There remain critical gaps in research, including the exploration of effective transdiagnostic interventions. This forum article examines the potential of psilocybin treatment (PT) as a transdiagnostic intervention for EDs and common comorbidities, including the implications for alternative nosological frameworks, trial design, and clinical care.MethodA narrative review was conducted synthesizing clinical, mechanistic, and conceptual literature on PT for EDs and common psychiatric comorbidities. Searches of academic databases were supplemented by hand-searching and clinical trial registries. Thematic synthesis focused on transdiagnostic clinical evidence, mechanistic theories, and implications for the Hierarchical Taxonomy of Psychopathology (HiTOP), Research Domain Criteria (RDoC), treatment development, and clinical trial design.ResultsPreliminary clinical evidence supports the feasibility, safety, and therapeutic effects of PT for EDs, with robust transdiagnostic effects observed across comorbid conditions. Proposed mechanisms (i.e., serotonergic receptor agonism, psychoplastogenic effects, neural network desynchronization) target shared vulnerabilities that map onto dimensional constructs in HiTOP (Emotional Dysfunction superspectrum, Internalizing spectrum) and RDoC (negative/positive valence, cognitive, and social process domains) nosologies. Future research should explore pragmatic trial designs and dimensional outcome measures to capture the real-world complexities of PT for EDs.DiscussionPT demonstrates transdiagnostic therapeutic potential for EDs, and the advancement of dimensional nosologies, complex intervention frameworks, and personalized treatment protocols may address existing gaps in research and clinical care.","journal":"International Journal of Eating Disorders","publication_date":"2026-07-01","publication_year":2026,"doi":"10.1002/eat.70164","pubmed_id":"42393007","source_url":"https://doi.org/10.1002/eat.70164","keywords":"","substance_tags":"psilocybin","source_name":"Europe PMC","date_added":"2026-07-04 01:20:05","last_checked":"2026-07-05 01:20:21","raw_json":"{\"europe_pmc_id\":\"42393007\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W7167014213\",\"openalex_url\":\"https://openalex.org/W7167014213\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1191653087\",\"https://openalex.org/W1931781407\",\"https://openalex.org/W1944481685\",\"https://openalex.org/W1968733266\",\"https://openalex.org/W1969577526\",\"https://openalex.org/W1972883514\",\"https://openalex.org/W1976624064\",\"https://openalex.org/W1985513874\",\"https://openalex.org/W1986348004\",\"https://openalex.org/W2006378117\",\"https://openalex.org/W2007644698\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2030842831\",\"https://openalex.org/W2043197532\",\"https://openalex.org/W2052565335\",\"https://openalex.org/W2052804935\",\"https://openalex.org/W2080055550\",\"https://openalex.org/W2093203605\",\"https://openalex.org/W2095960650\",\"https://openalex.org/W2115430216\",\"https://openalex.org/W2118540296\",\"https://openalex.org/W2120654343\",\"https://openalex.org/W2140540881\",\"https://openalex.org/W2298540806\",\"https://openalex.org/W2339503814\",\"https://openalex.org/W2567379065\",\"https://openalex.org/W2599264051\",\"https://openalex.org/W2623228771\",\"https://openalex.org/W2733159797\",\"https://openalex.org/W2740567311\",\"https://openalex.org/W2795870103\",\"https://openalex.org/W2807534705\",\"https://openalex.org/W2888612576\",\"https://openalex.org/W2892307734\",\"https://openalex.org/W2896480657\",\"https://openalex.org/W2900604419\",\"https://openalex.org/W2908155319\",\"https://openalex.org/W2914496888\",\"https://openalex.org/W2914520605\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W2979620240\",\"https://openalex.org/W2986368852\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W3007835064\",\"https://openalex.org/W3031144616\",\"https://openalex.org/W3049509808\",\"https://openalex.org/W3084249337\",\"https://openalex.org/W3087859780\",\"https://openalex.org/W3112525124\",\"https://openalex.org/W3120551831\",\"https://openalex.org/W3134803076\",\"https://openalex.org/W3135628799\",\"https://openalex.org/W3135635133\",\"https://openalex.org/W3136402846\",\"https://openalex.org/W3148497253\",\"https://openalex.org/W3153796079\",\"https://openalex.org/W3166604621\",\"https://openalex.org/W3194472989\",\"https://openalex.org/W3200757480\",\"https://openalex.org/W3204019137\",\"https://openalex.org/W4200408156\",\"https://openalex.org/W4205400385\",\"https://openalex.org/W4210332402\",\"https://openalex.org/W4280584826\",\"https://openalex.org/W4281891940\",\"https://openalex.org/W4292262959\",\"https://openalex.org/W4307093712\",\"https://openalex.org/W4310942020\",\"https://openalex.org/W4318933953\",\"https://openalex.org/W4319765908\",\"https://openalex.org/W4362656963\",\"https://openalex.org/W4376279493\",\"https://openalex.org/W4381548553\",\"https://openalex.org/W4384154266\",\"https://openalex.org/W4385664009\",\"https://openalex.org/W4386504040\",\"https://openalex.org/W4386606492\",\"https://openalex.org/W4387019277\",\"https://openalex.org/W4387521434\",\"https://openalex.org/W4389139111\",\"https://openalex.org/W4389975182\",\"https://openalex.org/W4390794276\",\"https://openalex.org/W4391893692\",\"https://openalex.org/W4396229906\",\"https://openalex.org/W4397049758\",\"https://openalex.org/W4398195443\",\"https://openalex.org/W4398782381\",\"https://openalex.org/W4399572299\",\"https://openalex.org/W4400364503\",\"https://openalex.org/W4401212791\",\"https://openalex.org/W4402221705\",\"https://openalex.org/W4403216984\",\"https://openalex.org/W4403509916\",\"https://openalex.org/W4404160271\",\"https://openalex.org/W4404286681\",\"https://openalex.org/W4404836981\",\"https://openalex.org/W4405376152\",\"https://openalex.org/W4406338182\",\"https://openalex.org/W4408186822\",\"https://openalex.org/W4408221975\",\"https://openalex.org/W4408328158\",\"https://openalex.org/W4409313347\",\"https://openalex.org/W4409449345\",\"https://openalex.org/W4409687073\",\"https://openalex.org/W4409729252\",\"https://openalex.org/W4411355052\",\"https://openalex.org/W4411969620\",\"https://openalex.org/W4412489091\",\"https://openalex.org/W4412570375\",\"https://openalex.org/W4413411862\",\"https://openalex.org/W4413839750\",\"https://openalex.org/W4414072214\",\"https://openalex.org/W4414745665\",\"https://openalex.org/W4415622018\",\"https://openalex.org/W4417031290\",\"https://openalex.org/W4417397706\",\"https://openalex.org/W7125961702\",\"https://openalex.org/W7128441230\",\"https://openalex.org/W7133234785\",\"https://openalex.org/W7134072318\",\"https://openalex.org/W7134891055\",\"https://openalex.org/W7135170485\",\"https://openalex.org/W7148242223\"],\"authorships\":[{\"id\":\"https://openalex.org/A5060209926\",\"display_name\":\"Elena Koning\",\"orcid\":\"https://orcid.org/0000-0001-5241-0288\"},{\"id\":\"https://openalex.org/A5006203775\",\"display_name\":\"Jérémie Richard\",\"orcid\":\"https://orcid.org/0000-0001-9893-1353\"},{\"id\":\"https://openalex.org/A5023552725\",\"display_name\":\"Aaron Keshen\",\"orcid\":\"https://orcid.org/0000-0003-0462-9749\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S74080386\",\"source_display_name\":\"International Journal of Eating Disorders\",\"landing_page_url\":\"https://doi.org/10.1002/eat.70164\",\"is_oa\":false}}}","topic_tags":"Eating Disorders,Mechanism of Action,Receptor Pharmacology,Emotional Processing,Clinical Trial,Review Article,Safety","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7167014213"},{"id":3975,"title":"Sexual identity as a moderator of associations between lifetime MDMA/ecstasy or psilocybin use and mental health outcomes: An exploratory analysis of a nationally representative sample using NSDUH 2015-2019","normalized_title":"sexual identity as a moderator of associations between lifetime mdma ecstasy or psilocybin use and mental health outcomes an exploratory analysis of a nationally representative sample using nsduh 2015 2019","authors":"Seale M.","abstract":"Abstract Purpose Lifetime MDMA/ecstasy and psilocybin use have been associated with lower odds of psychological distress, suicidality, and depressive episodes, but these associations may vary by marginalized identity. Building on minorities' diminished psychedelic returns (MDPR) framework and extending Jones and Nock's race/ethnicity moderation work, this study tests whether sexual identity moderates them. Methods This cross-sectional secondary analysis used pooled NSDUH 2015-2019 data (N = 210,392 adults). Survey-weighted logistic regressions tested whether sexual identity moderated associations between lifetime MDMA/ecstasy or psilocybin use and six mental health outcomes. In a two-step exploratory design, full-sample interactions were screened first, with subgroup models tested only for substance-outcome combinations showing significant moderation (p ≤.05). Results Lifetime MDMA/ecstasy and psilocybin use were more common among bisexual and lesbian/gay than heterosexual respondents. Bisexual identity moderated psilocybin associations with past-year suicidal ideation (p =.03579) and severe past-year major depressive episode (MDE; p =.04950); no other interactions were significant. In subgroup models, psilocybin was associated with reduced severe past-year MDE among heterosexual (aOR = 0.85 [0.74, 0.98], p =.03170) but not bisexual respondents. No subgroups showed a psilocybin-suicidal-ideation association. Conclusion This data provides little support for MDPR as applied to sexual identity: most sexual-identity-by-substance interactions were null and none survived false-discovery-rate correction. The two psilocybin-bisexual signals are hypothesis-generating at most, but the bisexual specificity suggests differences in social and integration support may shape whether psychedelic exposure benefits mental health.","journal":"Research Square","publication_date":"2026-07-01","publication_year":2026,"doi":"10.21203/rs.3.rs-10208910/v1","pubmed_id":null,"source_url":"https://doi.org/10.21203/rs.3.rs-10208910/v1","keywords":"","substance_tags":"psilocybin","source_name":"Europe PMC","date_added":"2026-07-03 01:20:31","last_checked":"2026-07-05 01:20:16","raw_json":"{\"europe_pmc_id\":\"PPR1264241\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"Research Square\",\"importer\":\"Europe PMC\"}","topic_tags":"Depression,Observational Study,Drug Interactions","study_type":"Observational Study","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"preprint","openalex_id":null},{"id":3693,"title":"Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study","normalized_title":"consciousness and psilocybin effects on well being the copewell study","authors":"University of Wisconsin, Madison","abstract":"This study is exploring how psilocybin (a psychedelic drug) may improve mood and wellbeing. Many people report feeling better after taking psilocybin, but it is not clear why. The CoPEWell study will test whether these improvements come from the psychedelic experience itself (the \"trip\") or from direct effects on the brain. To study this, up to 120 participants will be enrolled to receive psilocybin either while awake or asleep and can expect to be on study for up to 4 months. Primary Objectives: 1. To evaluate the effect of psilocybin on wellbeing when administered while awake vs. while asleep 2. To evaluate the effect of psilocybin on wellbeing administered while asleep vs. placebo administered while asleep Secondary Objectives: 3. To evaluate the effect of psilocybin on psychological flexibility when administered while awake vs. while asleep 4. To evaluate the effect of psilocybin on psychological flexibility administered while asleep vs. placebo administered while asleep 5. To evaluate the effect of psilocybin on social connectedness when administered while awake vs. while asleep 6. To evaluate the effect of psilocybin on social connectedness administered while asleep vs. placebo administered while asleep 7. To evaluate the effect on wellbeing/life satisfaction/purpose/meaning explicitly ascribed to psilocybin administered while awake vs. while asleep 8. To evaluate the effect on wellbeing/life satisfaction/purpose/meaning explicitly ascribed to psilocybin administered while asleep vs. saline placebo administered while asleep","journal":"ClinicalTrials.gov","publication_date":"2026-07-01","publication_year":2026,"doi":null,"pubmed_id":null,"source_url":"https://clinicaltrials.gov/study/NCT07360301","keywords":"Well-Being, Psychological, Psychedelic Experiences, Psilocybin, intravenous psilocybin, Saline Placebo, Clonidine, Clonidine ER, NOT_YET_RECRUITING","substance_tags":"psilocybin","source_name":"ClinicalTrials.gov","date_added":"2026-07-01 11:04:28","last_checked":"2026-07-05 01:22:40","raw_json":"{\"nct_id\":\"NCT07360301\",\"overall_status\":\"NOT_YET_RECRUITING\",\"phase\":[\"PHASE1\"]}","topic_tags":"Consciousness,Wellbeing,Psychological Flexibility","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"clinical trial","openalex_id":null},{"id":3980,"title":"Psilocybin helps woman with Alzheimer's","normalized_title":"psilocybin helps woman with alzheimer s","authors":"Busby Mattha","abstract":"","journal":"New Scientist","publication_date":"2026-06-30","publication_year":2026,"doi":"10.1016/s0262-4079(26)01034-1","pubmed_id":null,"source_url":"https://doi.org/10.1016/s0262-4079(26)01034-1","keywords":"","substance_tags":"psilocybin","source_name":"Crossref","date_added":"2026-07-04 01:20:27","last_checked":"2026-07-05 01:20:21","raw_json":"{\"doi\":\"10.1016/s0262-4079(26)01034-1\",\"reference_dois\":[],\"reference_count\":0,\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W7167250009\",\"openalex_url\":\"https://openalex.org/W7167250009\",\"openalex_relevance_score\":4,\"openalex_relevance_reasons\":[\"title:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5079369039\",\"display_name\":\"Mattha Busby\",\"orcid\":null}],\"primary_location\":{\"source_id\":\"https://openalex.org/S104920066\",\"source_display_name\":\"The New Scientist\",\"landing_page_url\":\"https://doi.org/10.1016/s0262-4079(26)01034-1\",\"is_oa\":false}}}","topic_tags":"General","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7167250009"},{"id":3813,"title":"Convergent biosynthesis of psilocybin in an ectomycorrhizal lineage: is the psychoactive end-product the selected trait?","normalized_title":"convergent biosynthesis of psilocybin in an ectomycorrhizal lineage is the psychoactive end product the selected trait","authors":"Askari M, Surapaneni V.","abstract":"The fungivore-deterrence hypothesis, that psilocybin evolved as a chemical defence against arthropod fungivores via 5-HT receptor agonism, has become the working consensus in fungal chemical ecology, despite resting on a phylogenomic pattern of horizontal gene transfer among saprotrophs and remarkably little direct experimental evidence. Recent biochemistry shows that the ectomycorrhizal Inocybe corydalina assembles psilocybin through a convergently evolved, non-homologous ips cluster whose branched pathway yields baeocystin, not psilocybin, as the primary end-product. We argue that psilocybin's psychoactivity at vertebrate 5-HT2A receptors is plausibly incidental, with selection most likely acting on the injury-triggered polymerized indoloquinoid end-state of the blueing reaction (with psilocybin functioning as its stable storage precursor) and only secondarily on the monomeric congeners baeocystin or aeruginascin. We propose a five-tier comparative experimental program to adjudicate among these alternatives.","journal":"EcoEvoRxiv","publication_date":"2026-06-30","publication_year":2026,"doi":"10.32942/x2fd49","pubmed_id":null,"source_url":"https://doi.org/10.32942/x2fd49","keywords":"","substance_tags":"psilocybin","source_name":"Europe PMC","date_added":"2026-07-02 20:31:02","last_checked":"2026-07-05 01:20:21","raw_json":"{\"europe_pmc_id\":\"PPR1263823\",\"source\":\"PPR\",\"pub_type\":null,\"publisher\":\"EcoEvoRxiv\",\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W7166796269\",\"openalex_url\":\"https://openalex.org/W7166796269\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[],\"authorships\":[{\"id\":\"https://openalex.org/A5139727248\",\"display_name\":\"Mellica Askari\",\"orcid\":\"https://orcid.org/0009-0005-1876-7714\"},{\"id\":\"https://openalex.org/A5135689316\",\"display_name\":\"Varun Surapaneni\",\"orcid\":null}],\"primary_location\":{\"source_id\":null,\"source_display_name\":null,\"landing_page_url\":\"https://doi.org/10.32942/x2fd49\",\"is_oa\":true}}}","topic_tags":"Mechanism of Action,Receptor Pharmacology,Genomics","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"preprint","openalex_id":"https://openalex.org/W7166796269"},{"id":3812,"title":"Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health Symptoms","normalized_title":"past year psilocybin and alcohol co use associations with mental health symptoms","authors":"Hummel Haley M., Obrochta Alexia N., Kerr David C. R., Cservenka Anita","abstract":"Interest has grown in the effects of psilocybin on mental health, but little is known about its naturalistic use alongside alcohol and its relationship to depression and/or anxiety symptoms. Data from the nationally-representative 2024 National Survey Investigating Hallucinogenic Trends of participants who did ( n = 1234) or did not ( n = 1607) report past-year psilocybin and alcohol co-use were compared on depressive and anxiety symptoms and poor mental health days. Weighted regressions adjusted for age, sex, survey collection period, race, ethnicity, and past-year cannabis and other psychedelic use. Individuals with psilocybin and alcohol co-use had fewer depressive symptoms ( B (SE) = −.57(.28), β = −.04, p =.043) than those who used alcohol without psilocybin, suggesting potential benefits of psilocybin in individuals with co-use. After removing cannabis and other psychedelic use covariates, psilocybin use was also related to lower anxiety symptoms. However, given the observational and self-report study design, causal inferences cannot be made. Thus, longitudinal and experimental studies are needed.","journal":"Journal of Drug Issues","publication_date":"2026-06-30","publication_year":2026,"doi":"10.1177/00220426261466154","pubmed_id":null,"source_url":"https://doi.org/10.1177/00220426261466154","keywords":"","substance_tags":"psilocybin","source_name":"Crossref","date_added":"2026-07-02 06:54:51","last_checked":"2026-07-05 01:20:21","raw_json":"{\"doi\":\"10.1177/00220426261466154\",\"reference_dois\":[\"10.52965/001c.127794\",\"10.2196/15830\",\"10.1001/jamahealthforum.2025.4011\",\"10.1007/s11469-023-01163-2\",\"10.1111/acer.14518\",\"10.1111/adb.13229\",\"10.15288/jsa.1993.54.326\",\"10.1037/1040-3590.6.2.117\",\"10.1080/09687637.2023.2236291\",\"10.20944/preprints202506.1536.v1\",\"10.1097/01.alc.0000081617.37539.d6\",\"10.3389/fpsyt.2019.00955\",\"10.1016/j.psychres.2020.112749\",\"10.1016/j.jad.2023.01.108\",\"10.15288/jsad.23-00312\",\"10.1016/j.dscb.2025.100286\",\"10.1080/02791072.2022.2044096\",\"10.15288/jsa.2001.62.190\",\"10.1001/jamapsychiatry.2025.3038\",\"10.1556/2054.2023.00243\",\"10.1007/s00213-011-2236-1\",\"10.1016/j.biopsych.2014.04.010\",\"10.1046/j.1525-1497.2001.016009606.x\",\"10.1016/j.drugpo.2024.104507\",\"10.1177/02698811241292956\",\"10.3390/molecules26102948\",\"10.1016/0306-4603(96)00042-1\",\"10.1136/bmj-2023-078084\",\"10.3389/fpsyt.2024.1429373\",\"10.3389/fpsyt.2023.1199642\",\"10.1038/s41429-020-0311-8\",\"10.1073/pnas.1524187113\",\"10.1111/add.13757\",\"10.1176/appi.ajp.2019.19010035\",\"10.7326/annals-24-03145\",\"10.3389/fpsyg.2021.729425\",\"10.1038/s44220-026-00630-8\",\"10.1001/archinte.166.10.1092\",\"10.1080/02791072.2022.2039815\",\"10.1038/nrn2884\",\"10.1146/annurev-psych-040422-045007\"],\"reference_count\":50,\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W7166830239\",\"openalex_url\":\"https://openalex.org/W7166830239\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W2022417404\",\"https://openalex.org/W2043705607\",\"https://openalex.org/W2068751924\",\"https://openalex.org/W2093203605\",\"https://openalex.org/W2112692374\",\"https://openalex.org/W2118588896\",\"https://openalex.org/W2129497492\",\"https://openalex.org/W2132322340\",\"https://openalex.org/W2139781346\",\"https://openalex.org/W2167163337\",\"https://openalex.org/W2336591896\",\"https://openalex.org/W2589841225\",\"https://openalex.org/W2981471416\",\"https://openalex.org/W2996870046\",\"https://openalex.org/W3001327571\",\"https://openalex.org/W3006905788\",\"https://openalex.org/W3025824861\",\"https://openalex.org/W3102139776\",\"https://openalex.org/W3161556967\",\"https://openalex.org/W3204171992\",\"https://openalex.org/W4213229867\",\"https://openalex.org/W4214488648\",\"https://openalex.org/W4293870301\",\"https://openalex.org/W4294308393\",\"https://openalex.org/W4319067008\",\"https://openalex.org/W4323049021\",\"https://openalex.org/W4385304034\",\"https://openalex.org/W4386861633\",\"https://openalex.org/W4387035369\",\"https://openalex.org/W4396588878\",\"https://openalex.org/W4400043767\",\"https://openalex.org/W4401821604\",\"https://openalex.org/W4403848501\",\"https://openalex.org/W4403895310\",\"https://openalex.org/W4406091421\",\"https://openalex.org/W4409632414\",\"https://openalex.org/W4411500561\",\"https://openalex.org/W4414440106\",\"https://openalex.org/W4415929140\",\"https://openalex.org/W4416008630\",\"https://openalex.org/W7151101131\"],\"authorships\":[{\"id\":\"https://openalex.org/A5107648241\",\"display_name\":\"Haley M Hummel\",\"orcid\":null},{\"id\":\"https://openalex.org/A5116118092\",\"display_name\":\"Alexia N Obrochta\",\"orcid\":null},{\"id\":\"https://openalex.org/A5139789016\",\"display_name\":\"David C. R. Kerr\",\"orcid\":null},{\"id\":\"https://openalex.org/A5088076764\",\"display_name\":\"Anita Cservenka\",\"orcid\":\"https://orcid.org/0000-0003-0813-5201\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S57770130\",\"source_display_name\":\"Journal of Drug Issues\",\"landing_page_url\":\"https://doi.org/10.1177/00220426261466154\",\"is_oa\":false}}}","topic_tags":"Depression,Anxiety,Observational Study","study_type":"Observational Study","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7166830239"},{"id":3811,"title":"Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review.","normalized_title":"investigating the impact of serotonergic psychedelic drugs mdma and ketamine on social cognition in psychiatric disorders a scoping review","authors":"Smith SA, Mohammad H, Lee LHN, Dennett L, Smith S, Burback L, Winkler O, Greenshaw A, Jetly R, Kennedy SH, Bhat V, Swainson J, Vermetten E, Cao B, Li XM, Zhang Y.","abstract":"RationaleInterest in psychedelic drugs has increased rapidly because of their potential therapeutic role in psychiatric disorders. Impairments in the sociocognitive skills needed to build and maintain social relationships are prominent features of many psychiatric and neurodevelopmental disorders. Emerging evidence suggests that compounds such as 3,4-methylenedioxymethamphetamine (MDMA), lysergic acid diethylamide (LSD), and psilocybin may influence these impairments.ObjectivesThis review aimed to determine whether psychedelic drugs may modulate social cognition in individuals with psychiatric or neurodevelopmental disorders associated with cognitive impairment.MethodsA search of the MEDLINE, PsycINFO, EMBASE, and Scopus databases was conducted. Twenty studies were identified that evaluated the effects of ketamine, MDMA, psilocybin, LSD, and ayahuasca in depressive disorders, anxiety disorders, autism spectrum disorder (ASD), and post-traumatic stress disorder (PTSD).ResultsFindings included neural activation patterns suggesting that ketamine and psilocybin may modulate processes relevant to social perception, particularly facial emotion processing, in depressive disorders. Positive findings were also reported for MDMA in participants with PTSD, including improvements in self-reported psychosocial functioning, self-awareness, and self-compassion.ConclusionsCurrent evidence suggests that psychedelic drugs may modulate processes relevant to social cognition in psychiatric disorders, although direct evidence of improved social-cognitive functioning remains limited.Clinical trial numberNot applicable.","journal":null,"publication_date":"2026-06-30","publication_year":2026,"doi":"10.1007/s00213-026-07110-y","pubmed_id":"42380668","source_url":"https://doi.org/10.1007/s00213-026-07110-y","keywords":"","substance_tags":"psilocybin","source_name":"Europe PMC","date_added":"2026-07-01 13:00:05","last_checked":"2026-07-05 01:20:16","raw_json":"{\"europe_pmc_id\":\"42380668\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}","topic_tags":"Depression,Anxiety,PTSD,Emotional Processing,Clinical Trial,Review Article","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":null},{"id":3662,"title":"Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms","normalized_title":"efficacy in relapse prevention psilocybin in alcohol use disorder with depressive symptoms","authors":"Centre Hospitalier Universitaire de Nīmes","abstract":"Up to 40% of individuals with alcohol use disorder (AUD) experience depression, which increases the risk of early relapse. Depression can cause relapse to occur 3 times faster in individuals with AUD who experience depressive symptoms at discharge. No treatments have been approved for individuals with both AUD and depression. Psilocybin, a psychedelic, shows promising results in treating both depression and addiction. It may be particularly effective for preventing relapse in people with AUD who also have depressive symptoms after detoxification, offering quicker action than traditional antidepressants. The Psilocybin Alcohol Depression (PAD) pilot study, launched in February 2024, has provided critical insights for avoiding methodological flaws and demonstrated that psilocybin-assisted psychotherapy (PAP) is both feasible and acceptable. Preliminary efficacy analyses were conducted: at 12 weeks, the 25 mg group showed significantly greater reductions in drinking days (p = 0.038) and craving frequency (p = 0.045). Relapse rates were 35% in the 25 mg group and 50% in the control group (HR = 0.52 \\[0.16-1.65\\]). In the ERPPAD trial, the study authors will compare high-dose PAP with low-dose PAP in preventing relapse in individuals with AUD and depressive symptoms. The hypothesis is that high-dose PAP will be more effective than low-dose in preventing relapse over 6 months.","journal":"ClinicalTrials.gov","publication_date":"2026-06-30","publication_year":2026,"doi":null,"pubmed_id":null,"source_url":"https://clinicaltrials.gov/study/NCT07638553","keywords":"Alcohol Use Disorder, Depressive Sympotoms, Psilocybin, Psilocybin (high dose), Psilocybin (low dose), RECRUITING","substance_tags":"psilocybin","source_name":"ClinicalTrials.gov","date_added":"2026-07-01 11:04:28","last_checked":"2026-07-05 01:22:40","raw_json":"{\"nct_id\":\"NCT07638553\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE3\"]}","topic_tags":"Depression,Addiction,Safety","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"clinical trial","openalex_id":null},{"id":3547,"title":"A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)","normalized_title":"a phase 2 open label study investigating the safety and efficacy of psilocybin assisted therapy for sexual assault related posttraumatic stress disorder ptsd","authors":"Sunstone Medical","abstract":"A Phase 2, Open-Label Study to explore the efficacy, safety, and tolerability of psilocybin-assisted therapy in women with sexual assault-related Posttraumatic Stress Disorder (PTSD).","journal":"ClinicalTrials.gov","publication_date":"2026-06-30","publication_year":2026,"doi":null,"pubmed_id":null,"source_url":"https://clinicaltrials.gov/study/NCT06902974","keywords":"Post Traumatic Stress Disorder, PTSD, Psilocybin 25 mg, Psilocybin-assisted therapy, RECRUITING","substance_tags":"psilocybin","source_name":"ClinicalTrials.gov","date_added":"2026-07-01 11:04:28","last_checked":"2026-07-05 01:22:40","raw_json":"{\"nct_id\":\"NCT06902974\",\"overall_status\":\"RECRUITING\",\"phase\":[\"PHASE2\"]}","topic_tags":"PTSD,Clinical Trial,Safety","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"clinical trial","openalex_id":null},{"id":3002,"title":"Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits.","normalized_title":"modeled long term effects of psilocybin on dynamic activity and effective connectivity of fronto striatal thalamic circuits","authors":"Pasquini L, Vohryzek J, Escrichs A, Perl YS, Ponce-Alvarez A, Idesis S, Girn M, Roseman L, Mitchell JM, Gazzaley A, Kringelbach M, Nutt DJ, Lyons T, Carhart-Harris RL, Deco G.","abstract":"Psilocybin has been shown to induce fast and sustained symptoms improvements across various psychiatric conditions, yet its long-term mechanisms of action are not fully understood. Initial evidence suggests that longitudinal functional and structural brain changes implicate fronto-striatal-thalamic (FST) circuitry, a broad system involved in goal-directed behavior and motivational states. Here, we performed secondary analyses and applied computational modeling to resting-state fMRI data from a within-subject longitudinal psilocybin trial in psychedelic-naïve healthy volunteers. We first showed that dynamic FST activity increased 4 weeks after a full dose of psilocybin. We then proceeded to mechanistically account for these changes by providing tentative model-based support that reductions in the structure-function coupling contribute to increased dynamic FST activity postpsilocybin. Finally, we used computational approaches to show that psilocybin induces longitudinal increases in bottom-up and reduced top-down modulation of FST circuits. We then used publicly available receptor maps to show that cortical reductions in top-down modulation are linked to regional 5-HT2A receptor availability, while increased information outflow via subcortical and limbic regions relates to local D2 receptor availability. Together, these findings suggest that increased FST flexibility weeks after a high dose of psilocybin is linked to serotonergic-mediated decreases in top-down information flow and dopaminergic-mediated increases in bottom-up information flow. This long-term functional re-organization of FST circuits may represent a common mechanism contributing to the potential clinical efficacy of psilocybin across various neuropsychiatric disorders including substance abuse, major depression, and anorexia nervosa.","journal":"Human Brain Mapping","publication_date":"2026-06-30","publication_year":2026,"doi":"10.1002/hbm.70596","pubmed_id":"42381187","source_url":"https://doi.org/10.1002/hbm.70596","keywords":"Thalamus, Corpus Striatum, Frontal Lobe, Nerve Net, Neural Pathways, Humans, Hallucinogens, Magnetic Resonance Imaging, Longitudinal Studies, Models, Neurological, Adult, Female, Male, Young Adult, Connectome, Psilocybin","substance_tags":"psilocybin","source_name":"Europe PMC","date_added":"2026-07-01 11:03:06","last_checked":"2026-07-05 01:20:21","raw_json":"{\"europe_pmc_id\":\"42381187\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\",\"openalex_enrichment\":{\"openalex_id\":\"https://openalex.org/W7166854327\",\"openalex_url\":\"https://openalex.org/W7166854327\",\"openalex_relevance_score\":9,\"openalex_relevance_reasons\":[\"title:psilocybin\",\"abstract:psilocybin\",\"metadata:psilocybin\"],\"openalex_type\":\"article\",\"openalex_work_type\":null,\"cited_by_count\":0,\"referenced_works\":[\"https://openalex.org/W1748789401\",\"https://openalex.org/W2026832357\",\"https://openalex.org/W2046230471\",\"https://openalex.org/W2058046532\",\"https://openalex.org/W2064319583\",\"https://openalex.org/W2116031726\",\"https://openalex.org/W2506717582\",\"https://openalex.org/W2525626228\",\"https://openalex.org/W2597410197\",\"https://openalex.org/W2608583841\",\"https://openalex.org/W2798279033\",\"https://openalex.org/W2893373014\",\"https://openalex.org/W2894570760\",\"https://openalex.org/W2911514809\",\"https://openalex.org/W2949457836\",\"https://openalex.org/W2969829800\",\"https://openalex.org/W3014803974\",\"https://openalex.org/W3015902292\",\"https://openalex.org/W3034488128\",\"https://openalex.org/W3084035636\",\"https://openalex.org/W3096208965\",\"https://openalex.org/W3118861474\",\"https://openalex.org/W3156937150\",\"https://openalex.org/W3175441262\",\"https://openalex.org/W3179473685\",\"https://openalex.org/W3185074371\",\"https://openalex.org/W3205085416\",\"https://openalex.org/W4200471428\",\"https://openalex.org/W4211211437\",\"https://openalex.org/W4213347163\",\"https://openalex.org/W4225144612\",\"https://openalex.org/W4243954785\",\"https://openalex.org/W4281774703\",\"https://openalex.org/W4292791729\",\"https://openalex.org/W4292937262\",\"https://openalex.org/W4302424620\",\"https://openalex.org/W4306408159\",\"https://openalex.org/W4308146982\",\"https://openalex.org/W4316016059\",\"https://openalex.org/W4321033185\",\"https://openalex.org/W4390227433\",\"https://openalex.org/W4409843587\"],\"authorships\":[{\"id\":\"https://openalex.org/A5018132997\",\"display_name\":\"Lorenzo Pasquini\",\"orcid\":\"https://orcid.org/0000-0002-7899-7061\"},{\"id\":\"https://openalex.org/A5073642716\",\"display_name\":\"Jakub Vohryzek\",\"orcid\":\"https://orcid.org/0000-0003-0994-5054\"},{\"id\":\"https://openalex.org/A5027614540\",\"display_name\":\"Anira Escrichs\",\"orcid\":\"https://orcid.org/0000-0002-6482-9737\"},{\"id\":\"https://openalex.org/A5091490801\",\"display_name\":\"Yonatan Sanz Perl\",\"orcid\":\"https://orcid.org/0000-0002-1270-5564\"},{\"id\":\"https://openalex.org/A5059409168\",\"display_name\":\"Adrián Ponce-Alvarez\",\"orcid\":\"https://orcid.org/0000-0003-1446-7392\"},{\"id\":\"https://openalex.org/A5135135782\",\"display_name\":\"Sebastian Idesis\",\"orcid\":\"https://orcid.org/0000-0002-8158-1673\"},{\"id\":\"https://openalex.org/A5017398137\",\"display_name\":\"Manesh Girn\",\"orcid\":\"https://orcid.org/0000-0003-0455-4273\"},{\"id\":\"https://openalex.org/A5139783089\",\"display_name\":\"Leor Roseman\",\"orcid\":null},{\"id\":\"https://openalex.org/A5078452831\",\"display_name\":\"Jennifer Mitchell\",\"orcid\":\"https://orcid.org/0000-0002-7567-8129\"},{\"id\":\"https://openalex.org/A5032146606\",\"display_name\":\"Adam Gazzaley\",\"orcid\":null},{\"id\":\"https://openalex.org/A5110937167\",\"display_name\":\"Morten Kringelbach\",\"orcid\":null},{\"id\":\"https://openalex.org/A5016082897\",\"display_name\":\"David Nutt\",\"orcid\":\"https://orcid.org/0000-0002-1286-1401\"},{\"id\":\"https://openalex.org/A5035033638\",\"display_name\":\"Taylor Lyons\",\"orcid\":\"https://orcid.org/0000-0002-3118-7344\"},{\"id\":\"https://openalex.org/A5139833133\",\"display_name\":\"Robin L. Carhart-Harris\",\"orcid\":null},{\"id\":\"https://openalex.org/A5047963275\",\"display_name\":\"Gustavo Deco\",\"orcid\":\"https://orcid.org/0000-0002-8995-7583\"}],\"primary_location\":{\"source_id\":\"https://openalex.org/S121666818\",\"source_display_name\":\"Human Brain Mapping\",\"landing_page_url\":\"https://doi.org/10.1002/hbm.70596\",\"is_oa\":true}}}","topic_tags":"Depression,Eating Disorders,Brain Imaging,Mechanism of Action,Receptor Pharmacology,Aging,Healthy Volunteers","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":"https://openalex.org/W7166854327"},{"id":1920,"title":"Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review","normalized_title":"revealing shortcomings in the assessment of psilocybin effects on ocd related symptoms in preclinical and clinical studies a systematic review","authors":"Jalalian-Javadpour Marzieh, Yekta Batool Ghorbani, Reyhani Niloufar, Hajizamani Shadi, Azizi Ali, Azad Najma Khoshrooz, Mohammadi Hamidreza, Vaseghi Salar","abstract":"","journal":"Journal of Affective Disorders Reports","publication_date":"2026-06-30","publication_year":2026,"doi":"10.1016/j.jadr.2026.101098","pubmed_id":null,"source_url":"https://doi.org/10.1016/j.jadr.2026.101098","keywords":"","substance_tags":"psilocybin","source_name":"Crossref","date_added":"2026-07-01 06:49:23","last_checked":"2026-07-05 01:20:15","raw_json":"{\"doi\":\"10.1016/j.jadr.2026.101098\",\"reference_dois\":[\"10.1007/s00213-024-06566-0\",\"10.1080/15622975.2016.1190867\",\"10.1038/s41598-020-59282-y\",\"10.1177/0269881114565144\",\"10.1038/s41380-024-02786-0\",\"10.1007/s00213-022-06286-3\",\"10.1016/s2215-0366(16)30065-7\",\"10.1097/j.pbj.0000000000000128\",\"10.3389/fpsyt.2025.1726818\",\"10.1093/ijnp/pyae057\",\"10.1001/jamapsychiatry.2020.3285\",\"10.1176/appi.ajp.2013.13040574\",\"10.1016/j.pnpbp.2005.11.005\",\"10.1016/j.neuropharm.2025.110648\",\"10.1016/j.neuropharm.2024.110202\",\"10.1037/bne0000579\",\"10.1001/archgenpsychiatry.2010.116\",\"10.3389/fpsyt.2023.1221131\",\"10.1073/pnas.2022489118\",\"10.3389/fphar.2021.640241\",\"10.1097/fbp.0000000000000757\",\"10.1192/bjo.2023.535\",\"10.1002/(sici)1096-9861(20000214)417:3<337::aid-cne7>3.0.co;2-o\",\"10.1097/fbp.0000000000000813\",\"10.1177/0269881120959614\",\"10.2139/ssrn.6218466\",\"10.1007/s00210-023-02843-5\",\"10.1016/j.heliyon.2022.e12135\",\"10.1038/s41380-023-02280-z\",\"10.1007/s00213-024-06644-3\",\"10.1371/journal.pone.0063972\",\"10.1586/14737175.9.2.255\",\"10.1192/bjo.2025.10895\",\"10.3389/fphar.2024.1391412\",\"10.1080/02791072.2020.1849879\",\"10.1016/j.celrep.2018.05.022\",\"10.3389/fpsyt.2022.1040217\",\"10.1177/02698811241269751\",\"10.1038/s41386-019-0324-9\",\"10.1177/02698811231205692\",\"10.1271/bbb.90095\",\"10.3114/fuse.2024.14.14\",\"10.1177/0269881119895520\",\"10.1177/02698811261424214\",\"10.4088/jcp.v67n1110\",\"10.1007/s00210-025-03912-7\",\"10.1016/j.pharmthera.2003.11.002\",\"10.1016/j.bbr.2020.113093\",\"10.1038/nrn3746\",\"10.1136/pgmj.57.671.543\",\"10.1016/j.comppsych.2025.152619\",\"10.1038/s41380-019-0431-3\",\"10.3389/fnbeh.2014.00180\",\"10.3390/ijms22020835\",\"10.1017/s1461145701002401\",\"10.1038/s41386-024-01794-6\",\"10.32598/bcn.2021.1920.2\",\"10.1016/j.neuron.2021.06.008\",\"10.1016/j.biopsych.2011.06.023\",\"10.1038/s41398-023-02456-9\",\"10.1038/s41572-019-0102-3\",\"10.1503/jpn.150012\",\"10.1007/s00228-024-03680-y\",\"10.1016/j.euroneuro.2013.12.006\",\"10.1016/j.jpsychires.2025.11.021\",\"10.1016/j.pnpbp.2024.111243\",\"10.1080/02791072.2014.963754\",\"10.1002/(sici)1098-2396(199709)27:1<79::aid-syn8>3.0.co;2-a\",\"10.1136/gpsych-2023-101208\",\"10.1177/02698811241249436\"],\"reference_count\":78}","topic_tags":"OCD,Systematic Review,Review Article,Animal Study","study_type":"Systematic Review","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":null},{"id":107,"title":"Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.","normalized_title":"implementing psilocybin assisted therapy in palliative care settings a survey of stakeholders","authors":"Plourde L, Chang SL, Nguyen O, Garel N, Farzin H, Stephan JF, Fallu JS, Dorval M, P3A Research Group","abstract":"While the adoption of psilocybin-assisted therapy for existential distress offers promising support for patients with life-threatening illnesses, implementing this intervention into palliative care settings presents significant real-world challenges. To examine palliative care stakeholders' knowledge and attitudes regarding psilocybin-assisted therapy, and identify barriers and facilitators to its implementation. We conducted a cross-sectional online survey between April 15 and December 18, 2024. The survey assessed perceived knowledge, attitudes, and perceived barriers and facilitators to the effective integration of psilocybin-assisted therapy into palliative care settings. One hundred and twenty-one adults involved in palliative care (physicians, other healthcare professionals, caregivers, and managers) were recruited from Canada's four most populous provinces: Québec, Ontario, Alberta, and British Columbia. Forty-three percent of stakeholders reported having good knowledge of psilocybin's potential benefits and risks. Attitudes towards psilocybin-assisted therapy were predominantly non-favourable (61%), yet varied across occupational groups ( Translating the potential of psilocybin-assisted therapy for existential distress from clinical trials into palliative care settings requires careful consideration and collaboration with stakeholders. Given the significant divergence in perspectives between clinical and non-clinical groups, tailored interprofessional education could help build shared understanding and support effective implementation. Being conducted in Canada, transferability to different regulatory frameworks may be limited.","journal":"Palliative medicine","publication_date":"2026-06-30","publication_year":2026,"doi":"10.1177/02692163261446141","pubmed_id":"42154482","source_url":"https://pubmed.ncbi.nlm.nih.gov/42154482/","keywords":"attitude of health personnel, hallucinogens, palliative care, psilocybin, surveys and questionnaires","substance_tags":"psilocybin","source_name":"PubMed","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-05 01:20:06","raw_json":"{\"pubmed_id\":\"42154482\"}","topic_tags":"End-of-Life Distress,Clinical Trial,Observational Study,Safety","study_type":"Clinical Trial","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":null},{"id":101,"title":"Psilocybin induces stereotyped movements and reduces defensive responding in planarians through 5-hydroxytryptamine mechanisms.","normalized_title":"psilocybin induces stereotyped movements and reduces defensive responding in planarians through 5 hydroxytryptamine mechanisms","authors":"Akbar RJ, Stringer AD, Wiah S, Dachepalli M, Daws SE, Inan S, Rawls SM.","abstract":"Psilocybin is a serotonergic 5-HT2A R agonist that causes psychedelic and anxiolytic effects in human users. To delineate conservation of psilocybin pharmacology, we investigated behavioral effects of psilocybin in planarians ( Dugesia dorotocephala ), the simplest living animal with cephalization that also has a well defined serotonin (5-hydroxytryptamine [5-HT]) system. We quantified stereotyped movements (e.g. head bops, twists, scrunches, and C-shapes) and defensive responding (negative phototaxis) and probed a 5-HT2A R mechanism for psilocybin using a selective 5-HT2A R antagonist (volinanserin). Psilocybin (0.01, 0.1, 1, and 10 nM) increased all stereotyped movements and, at higher concentrations, reduced motility. Volinanserin (1, 10, and 100 nM) did not induce any stereotyped movements or reduce motility. For combination experiments, volinanserin reduced cumulative stereotyped movements produced by psilocybin (0.01 nM) and specifically reduced psilocybin-evoked twists and head bops. Concentrations (","journal":null,"publication_date":"2026-06-30","publication_year":2026,"doi":"10.1097/fbp.0000000000000879","pubmed_id":"42186402","source_url":"https://doi.org/10.1097/fbp.0000000000000879","keywords":"Animals, Planarians, Serotonin, Hallucinogens, Stereotyped Behavior, Dose-Response Relationship, Drug, Psilocybin, Phototaxis","substance_tags":"psilocybin","source_name":"Europe PMC","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-05 01:20:16","raw_json":"{\"europe_pmc_id\":\"42186402\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}","topic_tags":"Pharmacology,Mechanism of Action,Receptor Pharmacology","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":null},{"id":58,"title":"MFCC-DFT mapping of ligand recognition at the 5-HT2A receptor: energetic analysis of the interactions between serotonin, psychedelics, and antipsychotics.","normalized_title":"mfcc dft mapping of ligand recognition at the 5 ht2a receptor energetic analysis of the interactions between serotonin psychedelics and antipsychotics","authors":"Junior WSC, Bezerra KS, Matias EGC, Oliveira JIN, Fulco UL.","abstract":"Mental disorders represent a major global health problem, with depression being one of the most prevalent and disabling conditions worldwide. Growing evidence suggests that the serotonergic system, particularly the 5-HT2A receptor, plays an important role in modulating mood and cognitive processes, constituting a key pharmacological target for several psychoactive compounds. In this study, we investigated the molecular interaction profile between the 5-HT2A receptor and four pharmacologically relevant ligands, serotonin (5-HT), psilocybin/psilocin (PSILO), lysergic acid diethylamide (LSD), and lumateperone (LMTP). Interaction energies were evaluated using the molecular fragmentation with conjugated caps (MFCC) method combined with density functional theory (DFT) calculations. Crystallographic structures were used as initial models, and residue-level interaction energies were calculated to identify the amino acids that contribute most to ligand stabilization at the receptor binding site. The results reveal that the complexes exhibit total interaction energies ranging from -35.38 to -71.98 kcal mol-1 under dielectric conditions representative of the protein environment. Key residues such as Asp155, Phe339, Leu229, and Val366 were identified as the main contributors to ligand stabilization in the studied systems, highlighting their role as structural anchors within the orthosteric binding pocket. Energy decomposition further revealed distinct interaction patterns associated with different regions of the ligand. Therefore, this study provides a detailed energetic characterization of ligand recognition in the 5-HT2A receptor and offers details that may contribute to the rational design of new serotonergic agents with potential for therapeutic applications.","journal":null,"publication_date":"2026-06-30","publication_year":2026,"doi":"10.1039/d6cp00943c","pubmed_id":"42300394","source_url":"https://doi.org/10.1039/d6cp00943c","keywords":"Humans, Serotonin, Lysergic Acid Diethylamide, Receptor, Serotonin, 5-HT2A, Antipsychotic Agents, Hallucinogens, Ligands, Binding Sites, Thermodynamics, Psilocybin, Heterocyclic Compounds, 4 or More Rings, Density Functional Theory","substance_tags":"psilocybin,psilocin","source_name":"Europe PMC","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-05 01:20:16","raw_json":"{\"europe_pmc_id\":\"42300394\",\"source\":\"MED\",\"pub_type\":null,\"publisher\":null,\"importer\":\"Europe PMC\"}","topic_tags":"Depression,Receptor Pharmacology,Drug Interactions","study_type":"Other","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":null},{"id":21,"title":"Chemistry/structural biology of psychedelic drugs and their receptor(s).","normalized_title":"chemistry structural biology of psychedelic drugs and their receptor s","authors":"Gumpper RH, Nichols DE","abstract":"This brief review highlights some of the structure-activity relationships of classic serotonergic psychedelics. In particular, we discuss structural features of three chemotypes: phenethylamines, ergolines and certain tryptamines, which possess psychedelic activity in humans. Where they are known, we point out the underlying molecular mechanisms utilized by each of the three chemotypes of psychedelic molecules. With a focus on the 5-HT receptor subtype, a G-protein coupled receptor known to be the primary target of psychedelics, we refer to several X-ray and cryoEM structures, with a variety of ligands bound, to illustrate the underlying atomistic basis for some of the known pharmacological observations of psychedelic drug actions. LINKED ARTICLES: This article is part of a themed issue Emerging Therapeutic Opportunities for Psychedelic and Related Drugs. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v183.14/issuetoc.","journal":"British journal of pharmacology","publication_date":"2026-06-30","publication_year":2026,"doi":"10.1111/bph.17361","pubmed_id":"39354889","source_url":"https://pubmed.ncbi.nlm.nih.gov/39354889/","keywords":"5-HT2A agonists, 5-HT2A receptor, LSD, Psychedelic chemotypes, crystal structures, docking, ergolines, phenethylamines, psilocybin, structural biology, structure-activity relationships, therapeutic potential, tryptamines","substance_tags":"psilocybin","source_name":"PubMed","date_added":"2026-06-30 22:38:07","last_checked":"2026-07-05 01:20:06","raw_json":"{\"pubmed_id\":\"39354889\"}","topic_tags":"Mechanism of Action,Receptor Pharmacology,Review Article","study_type":"Review Article","hidden":0,"false_positive":0,"curation_notes":null,"merged_into_id":null,"curation_locked":0,"publication_status":"published","openalex_id":null}],"total":4054,"page":1,"per_page":20,"pages":203,"resource":"papers","filters":{"q":null,"author":null,"substances":["psilocybin","psilocin"],"topic":null,"study_type":null,"cited_doi":null,"sources":[],"publication_statuses":[],"year":null,"journal":null,"from":null,"to":null,"sort":"newest","page":1,"per_page":"20"}}